dosage for ghk cu peptide injection KLOW & Protocol Guide ghk-cu peptide dosage safety injection

Who Should Avoid GHK-Cu Therapy

FOXO4-DRI is a senolytic peptide a D-retro-inverso peptide engineered to selectively eliminate senescent "zombie" cells that accumulate with age and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP)

Stock solutions of 110 mg/mL are typical and are then diluted into culture medium for working concentrations

Mild nausea or gut flushing: Rare, most often in patients starting at a higher dose than recommended

The peptide appears to shift macrophage polarization from pro-inflammatory M1 phenotypes toward anti-inflammatory M2 phenotypes, thereby facilitating tissue repair and regeneration